Pharmacokinetics-Pharmacodynamics: A Primer for the Clinical Microbiologist

Clinical Microbiology Newsletter

Volumn 33, Issue 17, 2011, Pages 127-131

  Iyer, Varsha ^a   Bhavnani, Sujata M ^a   Ambrose, Paul G ^a  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; DAPTOMYCIN; DORIPENEM; ERYTHROMYCIN; KETOLIDE; MONOBACTAM; ORITAVANCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; STREPTOMYCIN; TELAVANCIN; TICARCILLIN; TIGECYCLINE; TOBRAMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER; ACINETOBACTER INFECTION; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE FRACTIONATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; POSTANTIBIOTIC EFFECT; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA;

EID: 80051821570     PISSN: 01964399     EISSN: 18734391     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2011.08.001     Document Type: Article

References (13)

1. Ebert S.C., Craig W.A. Killing and re-growth of bacteria in vitro: a review. Scand. J. Infect. Dis. Suppl. 1991, 74:63-70.
2. Eagle H., Fleischman R., Levy M. "Continuous" vs. "discontinuous" therapy with penicillin: the effect of the interval between injections on therapeutic efficacy. N. Eng. J. Med. 1953, 248:481-488.
3. Vogelman B., et al. In vivo post-antibiotic effect in a thigh infection in neutropenic mice. J. Infect. Dis. 1988, 157:287-298.
4. Mouton J.W., et al. Standardization of pharmacokinetic-pharmacodynamic terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 2005, 55:601-607.
5. Craig W.A., Gudmundsson S. Post-antibiotic effect. Antibiotics in laboratory medicine 1996, 296-329. Williams & Wilkins, Baltimore, MD. 4th ed. V. Lorian (Ed.).
6. Bustamante C.I., Drusano G.L., Tatem B.A., Standiford HC Post-antibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1984, 26:678-682.
7. Andes, D.R. and W.A Craig. 2003. Pharmacodynamic activity of doripenem against multiple bacteria in a murine-thigh infection model, abstr. A-308. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother.
8. Craig W.A. Pharmacodynamics of antimicrobials: general concepts and applications. Antimicrobial pharmacodynamics in theory and clinical practice 2002, 1-20. Marcel Dekker, Inc., New York, NY. C.H. Nightingale, T. Murakawa, P.G. Ambrose (Eds.).
9. Ambrose P.G., et al. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated pneumonia bacterial pneumonia studies: look before you leap!. Clin. Infect. Dis. 2010, (Suppl. 1):S103-S110.
10. Ambrose P.G., et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 2007, 44:79-86.
11. Ambrose P.G., et al. Use of clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints. Diagn. Microbiol. Infect. Dis. 2009, 63:38-42.
12. Reid G.E., et al. Rapid development of Acinetobacter baumanii resistance to tigecycline. Pharmacotherapy 2007, 27:1198-1201.
13. Anthony K.B., et al. Clinical and Microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 2008, 46:567-570.